Subject(s)
Calcium Gluconate/administration & dosage , Hypocalcemia/prevention & control , Plateletpheresis/methods , Anticoagulants/adverse effects , Automation , Blood Donors , Citric Acid/adverse effects , Drug Evaluation , Female , Humans , Hypocalcemia/chemically induced , Infusions, Intravenous , Male , Plateletpheresis/instrumentationABSTRACT
CF was introduced in clinical medicine in 1980. Up to now, exclusively two-vein procedures have been carried out with some limitations to expansion of this technique. In this report we describe the very first application of single-needle CF carried out with Haemonetics MCS + apparatus. Twenty procedures were completed without any untoward effect in patients suffering from TTP, post-hepatitic cryoblobulinemia, familial hypercholesterolemia and acute Guillan-Barrè Syndrome. From 1 to 4 sessions were carried out per patient with the expected laboratory and clinical results. The only limit is the procedure time that averages 231 +/- 48 min., approximately 40% longer than two needle procedures.
Subject(s)
Plasmapheresis/methods , Cryoglobulinemia/therapy , Equipment Design , Female , Filtration , Guillain-Barre Syndrome/therapy , Humans , Hyperlipoproteinemia Type II/therapy , Male , Middle Aged , Plasmapheresis/instrumentation , Purpura, Thrombotic Thrombocytopenic/therapy , Treatment OutcomeABSTRACT
Autologous PBSC transplantation is an integral component of the management of hemato-oncology patients. In order to reduce the number of sessions needed to collect the desired number of repopulating cells there has been significant research activity in developing progressively more and more effective technologies and techniques. Recently our group has been involved in the rejuvenation of the MCS + apparatus for both platelet and PBSC collection. The so called "version A2 protocol" is aimed at collecting PBSC in a very efficient way. This protocol is characterized by high blood flow rates both in the collection and reinfusion (80 ml/min) recirculation (56 ml/min) and collection phases (30 ml/min). Only one recirculation is carried out every 5 cycles and only from 5 to 7 are carried out for a single procedure. Twenty-seven collections were carried out of which 25 were evaluable in terms of PBSC efficiency. These averaged 68.8% in an average procedure time of 3.5-5 h for processing an average of 7,052 ml of blood. The RBC contamination was reduced to approximately 5.02 g of hemoglobin and the average volume of the product to 177 ml. If these results are confirmed, the gap between CFC and DFC PBSC is progressively closing.
